Published on Apr 15, 2025 5 min read

Best Gene-Editing Stocks to Buy in 2023 for High Growth Potential

The field of gene editing has taken the world by storm, bringing with it a wave of excitement and potential in the healthcare sector. With advancements in gene therapy, CRISPR technology, and other innovative tools, gene-editing companies are not just changing the medical landscapethey are also offering investors a chance to capitalize on this rapidly growing market.

2024 is shaping up to be a pivotal year for the gene-editing industry, and if youre looking to invest in cutting-edge science, now might be the perfect time to consider some top gene-editing stocks. But with so many options out there, how do you identify the best picks for your portfolio? This article will highlight the most promising gene-editing stocks to buy for 2024, providing insights into their potential, challenges, and why they could be a game-changer for your investments.

What Makes Gene-Editing Stocks a Smart Investment?

The CRISPR-based platforms of gene-editing technology have now transformed from scientific curiosities to solutions for real-world applications to treat genetic disorders. Thus, these innovations will eventually mean the possibility of curing some untreatable diseases. That is why growth in the potential of gene-editing stocks is enormous.

One of the primary investment ideas for gene-editing stocks is the increasing requirement for precision medicine. Gene therapies now allow treatments to be formulated to match the genetic requirements of an individual patient- a type of personalization impossible earlier. The effectiveness, cost, and scalability of treatments based on CRISPR technology and other gene-editing techniques have made these more and more appealing not only to healthcare providers but also to investors.

The worldwide market for gene-edited products also is expected to grow drastically within the next decade. Today, in 2024, there are rapidly increasing numbers of clinical trials and research being led by multiple firms on the way to product launches in that space. Early investors in gene editing face a unique confluence of opportunity and great potential return. However, to maximize such an opportunity, a clear picture of which businesses are set to succeed is the key.

Top Gene-Editing Stocks to Buy for 2024

Editas Medicine (EDIT)

Editas Medicine is one of the pioneers in gene editing, focusing on developing therapies using CRISPR/Cas9 technology. The company is working on a range of genetic disorders, including sickle cell disease, retinal diseases, and beta-thalassemia. Editas has a solid pipeline of clinical trials, with some therapies expected to reach the market soon. Their commitment to cutting-edge research and their track record in gene editing makes them a solid choice for investors in 2024.

Editas is not without its challenges, though. Like many biotech firms, its success depends on the results of clinical trials, which can be unpredictable. However, the companys strong partnerships with major pharmaceutical companies like Allergan provide a solid foundation for its future. Given its advancements and high-profile backing, Editas is one of the top gene-editing stocks to consider this year.

Intellia Therapeutics (NTLA)

Intellia Therapeutics is another leader in the gene-editing space, specializing in CRISPR-based therapies for genetic diseases. The companys pipeline includes treatments for transthyretin amyloidosis, a serious neurodegenerative disease, and sickle cell disease, both of which are significant unmet medical needs.

Intellia has already made strides with its in vivo gene-editing technology, which delivers the CRISPR tool directly into the body to correct genetic defects. This technology is a significant advancement, as it could streamline the process of treating genetic disorders without the need for complicated procedures. With successful clinical trials and growing recognition in the scientific community, Intellia is poised to continue its upward trajectory in 2024.

CRISPR Therapeutics (CRSP)

Perhaps the most well-known name in the field, CRISPR Therapeutics, has become synonymous with gene editing. The company's flagship treatment, CTX001, has shown promising results in clinical trials for sickle cell disease and beta-thalassemia. CRISPR Therapeutics is also exploring other genetic conditions, positioning itself as a dominant player in the market.

CRISPRs robust intellectual property portfolio and its collaborations with companies like Vertex Pharmaceuticals strengthen its position in the market. Investors are excited by the companys rapid progress and the potential for CRISPR technology to revolutionize healthcare. With several treatments advancing through clinical trials, CRISPR Therapeutics remains a top pick for 2024.

Beam Therapeutics (BEAM)

Beam Therapeutics focuses on a slightly different approach to gene editing called base editing, which allows for the precise modification of individual DNA base pairs. This method is considered more accurate and efficient than traditional CRISPR, making it an attractive option for treating a variety of genetic disorders.

Beams portfolio includes treatments for sickle cell disease, beta-thalassemia, and certain rare genetic diseases. While still in the early stages of clinical trials, Beams unique approach to gene editing gives it a potential edge in the market. The companys promising technology, combined with strong financial backing, makes it an intriguing investment opportunity for those looking for exposure to cutting-edge gene-editing research.

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics is focused on using zinc finger nucleases (ZFNs) for gene editing, a technology that differs from CRISPR but holds significant promise. Sangamo is working on therapies for various genetic diseases, including hemophilia and sickle cell disease. The company has a broad portfolio of ongoing clinical trials, many of which are showing positive results.

Despite its potential, Sangamo faces some challenges in terms of competing with CRISPR-based companies, which have garnered more attention and investment. However, its unique approach and promising clinical trial results still make it a viable option for investors looking to diversify their gene-editing portfolio in 2024.

Conclusion

Gene-editing stocks are revolutionizing healthcare by tackling genetic disorders with cutting-edge technologies like CRISPR. While they carry risks tied to clinical trials and regulatory hurdles, their potential for long-term growth is immense. Companies such as Editas, Intellia, and CRISPR Therapeutics are in charge of innovative therapies and promising pipelines. For investors ready to embrace the challenges, gene-editing stocks in 2024 offer an exciting opportunity to participate in a transformative industry.